• Je něco špatně v tomto záznamu ?

Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study

M. Preusser, T. Kazda, E. Le Rhun, F. Sahm, M. Smits, J. Gempt, JA. Koekkoek, AF. Monti, M. Csanadi, JG. Pitter, H. Bulbek, B. Fournier, C. Quoilin, T. Gorlia, M. Weller, G. Minniti, European Organisation for Research, Treatment of Cancer (EORTC)...

. 2024 ; 25 (1) : 366. [pub] 20240607

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, protokol klinické studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013543

Grantová podpora
101103655 Horizon 2020 Framework Programme

BACKGROUND: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. METHODS: EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 score: 34 out of 45), randomized, multicenter phase III trial in patients with first progression of glioblastoma. A total of 411 patients will be randomized in a 1:1 ratio to lomustine (110 mg/m2 every 6 weeks) or lomustine (110 mg/m2 every 6weeks) plus radiotherapy (35 Gy in 10 fractions). Main eligibility criteria include histologic confirmation of glioblastoma, isocitrate dehydrogenase gene (IDH) wild-type per WHO 2021 classification, first progression at least 6 months after the end of prior radiotherapy, radiologically measurable disease according to RANO criteria with a maximum tumor diameter of 5 cm, and WHO performance status of 0-2. The primary efficacy endpoint is overall survival (OS) and secondary endpoints include progression-free survival, response rate, neurocognitive function, health-related quality of life, and health economic parameters. LEGATO is funded by the European Union's Horizon Europe Research program, was activated in March 2024 and will enroll patients in 43 sites in 11 countries across Europe with study completion projected in 2028. DISCUSSION: EORTC-2227-BTG (LEGATO) is a publicly funded pragmatic phase III trial designed to clarify the efficacy of adding reirradiation to chemotherapy with lomustine for the treatment of patients with first progression of glioblastoma. TRIAL REGISTRATION: ClinicalTrials.gov NCT05904119. Registered before start of inclusion, 23 May 2023.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013543
003      
CZ-PrNML
005      
20240905134100.0
007      
ta
008      
240725s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13063-024-08213-7 $2 doi
035    __
$a (PubMed)38849943
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Preusser, Matthias $u Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. matthias.preusser@meduniwien.ac.at $1 https://orcid.org/0000000335412315
245    10
$a Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study / $c M. Preusser, T. Kazda, E. Le Rhun, F. Sahm, M. Smits, J. Gempt, JA. Koekkoek, AF. Monti, M. Csanadi, JG. Pitter, H. Bulbek, B. Fournier, C. Quoilin, T. Gorlia, M. Weller, G. Minniti, European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group
520    9_
$a BACKGROUND: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. METHODS: EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 score: 34 out of 45), randomized, multicenter phase III trial in patients with first progression of glioblastoma. A total of 411 patients will be randomized in a 1:1 ratio to lomustine (110 mg/m2 every 6 weeks) or lomustine (110 mg/m2 every 6weeks) plus radiotherapy (35 Gy in 10 fractions). Main eligibility criteria include histologic confirmation of glioblastoma, isocitrate dehydrogenase gene (IDH) wild-type per WHO 2021 classification, first progression at least 6 months after the end of prior radiotherapy, radiologically measurable disease according to RANO criteria with a maximum tumor diameter of 5 cm, and WHO performance status of 0-2. The primary efficacy endpoint is overall survival (OS) and secondary endpoints include progression-free survival, response rate, neurocognitive function, health-related quality of life, and health economic parameters. LEGATO is funded by the European Union's Horizon Europe Research program, was activated in March 2024 and will enroll patients in 43 sites in 11 countries across Europe with study completion projected in 2028. DISCUSSION: EORTC-2227-BTG (LEGATO) is a publicly funded pragmatic phase III trial designed to clarify the efficacy of adding reirradiation to chemotherapy with lomustine for the treatment of patients with first progression of glioblastoma. TRIAL REGISTRATION: ClinicalTrials.gov NCT05904119. Registered before start of inclusion, 23 May 2023.
650    12
$a glioblastom $x patologie $x farmakoterapie $x mortalita $x radioterapie $x terapie $7 D005909
650    _2
$a lidé $7 D006801
650    12
$a lomustin $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D008130
650    12
$a nádory mozku $x radioterapie $x patologie $x mortalita $x terapie $7 D001932
650    12
$a progrese nemoci $7 D018450
650    12
$a alkylační protinádorové látky $x terapeutické užití $7 D018906
650    12
$a multicentrické studie jako téma $7 D015337
650    12
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a kvalita života $7 D011788
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a chemoradioterapie $x metody $7 D059248
650    _2
$a klinické zkoušky, fáze III jako téma $7 D017326
650    _2
$a pragmatické klinické studie jako téma $7 D064792
650    _2
$a časové faktory $7 D013997
655    _2
$a časopisecké články $7 D016428
655    _2
$a protokol klinické studie $7 D000078325
700    1_
$a Kazda, Tomáš $u Department of Radiation Oncology and Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Le Rhun, Emilie $u Department of Medical Oncology and Hematology, University Hospital & University of Zurich, Zurich, Switzerland
700    1_
$a Sahm, Felix $u Department of Neuropathology, University Hospital Heidelberg and CCU Neuropathology, DKFZ, Heidelberg, Germany
700    1_
$a Smits, Marion $u Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
700    1_
$a Gempt, Jens $u Department of Neurosurgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Koekkoek, Johan Af $u Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands
700    1_
$a Monti, Angelo F $u Department of Medical Physics, ASST GOM Niguarda, Milano, Italy
700    1_
$a Csanadi, Marcell $u Syreon Research Institute, Budapest, Hungary
700    1_
$a Pitter, János György $u Syreon Research Institute, Budapest, Hungary
700    1_
$a Bulbek, Helen $u Brainstrust-the brain cancer people, Isle of Wight, Cowes, UK
700    1_
$a Fournier, Beatrice $u EORTC Headquarters Team, Brussels, Belgium
700    1_
$a Quoilin, Caroline $u EORTC Headquarters Team, Brussels, Belgium
700    1_
$a Gorlia, Thierry $u EORTC Headquarters Team, Brussels, Belgium
700    1_
$a Weller, Michael $u Department of Neurology, University Hospital & University of Zurich, Zurich, Switzerland
700    1_
$a Minniti, Giuseppe $u Department of Radiological Sciences, Oncology and Anatomical Pathology and IRCCS Neuromed (IS), Sapienza University, Policlinico Umberto I, Rome, Italy
710    2_
$a European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group
773    0_
$w MED00163187 $t Trials $x 1745-6215 $g Roč. 25, č. 1 (2024), s. 366
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38849943 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134054 $b ABA008
999    __
$a ok $b bmc $g 2143388 $s 1225409
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 25 $c 1 $d 366 $e 20240607 $i 1745-6215 $m Trials $n Trials $x MED00163187
GRA    __
$a 101103655 $p Horizon 2020 Framework Programme
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace